Arie Belldegrun Allogene Therapeutics, Inc. (ALLO) insider trading activity

ALLO Quotes by TradingView

Arie Belldegrun is Director of Allogene Therapeutics, Inc.. Currently has a direct ownership of 2.24 Million shares of ALLO, which is worth approximately $3.58 Million. The most recent transaction as insider was on Jan 24, 2025, when has been sold 369,957 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.24M
19.82% 3M change
19.82% 12M change
Total Value Held $3.58 Million

Arie Belldegrun Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 24 2025
BUY
Grant, award, or other acquisition
-
369,957 Added 14.19%
2,236,816 Common Stock
Jan 25 2024
BUY
Grant, award, or other acquisition
-
211,973 Added 10.2%
1,866,859 Common Stock
Mar 22 2023
BUY
Grant, award, or other acquisition
-
1,282,976 Added 43.67%
1,654,886 Common Stock
May 24 2021
BUY
Exercise of conversion of derivative security
$6,906,582 $18.22 p/Share
379,066 Added 39.4%
583,034 Common Stock
Mar 26 2021
BUY
Grant, award, or other acquisition
-
53,635 Added 20.82%
203,968 Common Stock

Also insider at

KRON
Kronos Bio, Inc. Healthcare
URGN
UroGen Pharma Ltd. Healthcare
Director
DNA
Ginkgo Bioworks Holdings, Inc. Healthcare
Director
AB

Arie Belldegrun

Director
Princeton, NJ

Track Institutional and Insider Activities on ALLO

Follow Allogene Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALLO shares.

Notify only if

Insider Trading

Get notified when an Allogene Therapeutics, Inc. insider buys or sells ALLO shares.

Notify only if

News

Receive news related to Allogene Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ALLO